Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study

cc7788 CCJ Research Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study Nseir Saad s-nseir@chru-lille.fr Hoel Jérémy jeremy.hoel@wanadoo.fr Grailles Guillaume guirloute@hotmail.com Soury-Lavergne Aude a-sourylavergne@chru-lille.fr Di Pompeo Christophe cdipompeo@univ-lille2.fr Mathieu Daniel dmathieu@chru-lille.fr Durocher Alain a-durocher@chru-lille.fr

Intensive Care Unit, Calmette Hospital, University Hospital of Lille, boulevard du Pr Leclercq, 59037 Lille cedex, France

Medical Assessment Laboratory, Lille II University, 1 place de Verdun, 59045 Lille, France

Critical Care 1364-8535 2009 13 2 R60 http://ccforum.com/content/13/2/R60 19383164 10.1186/cc7788 12 12 2008 30 1 2009 04 3 2009 21 4 2009 21 4 2009 2009 Nseir et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction

Recent animal studies demonstrated immunosuppressive effects of opioid withdrawal resulting in a higher risk of infection. The aim of this study was to determine the impact of remifentanil discontinuation on intensive care unit (ICU)-acquired infection.

Methods

This was a prospective observational cohort study performed in a 30-bed medical and surgical university ICU, during a one-year period. All patients hospitalised in the ICU for more than 48 hours were eligible. Sedation was based on a written protocol including remifentanil with or without midazolam. Ramsay score was used to evaluate consciousness. The bedside nurse adjusted sedative infusion to obtain the target Ramsay score. Univariate and multivariate analyses were performed to determine risk factors for ICU-acquired infection.

Results

Five hundred and eighty-seven consecutive patients were included in the study. A microbiologically confirmed ICU-acquired infection was diagnosed in 233 (39%) patients. Incidence rate of ICU-acquired infection was 38 per 1000 ICU-days. Ventilator-associated pneumonia was the most frequently diagnosed ICU-acquired infection (23% of study patients). Pseudomonas aeruginosa was the most frequently isolated microorganism (30%). Multivariate analysis identified remifentanil discontinuation (odds ratio (OR) = 2.53, 95% confidence interval (CI) = 1.28 to 4.99, P = 0.007), simplified acute physiology score II at ICU admission (1.01 per point, 95% CI = 1 to 1.03, P = 0.011), mechanical ventilation (4.49, 95% CI = 1.52 to 13.2, P = 0.006), tracheostomy (2.25, 95% CI = 1.13 to 4.48, P = 0.021), central venous catheter (2.9, 95% CI = 1.08 to 7.74, P = 0.033) and length of hospital stay (1.05 per day, 95% CI = 1.03 to 1.08, P < 0.001) as independent risk factors for ICU-acquired infection.

Conclusions

Remifentanil discontinuation is independently associated with ICU-acquired infection.

Introduction

Healthcare-associated infections are the most common complications affecting hospitalised patients 1. Intensive care unit (ICU)-acquired infections represent the major part of these infections 2. In a recent multicentre study conducted in 71 adult ICUs 3, 7.4% of the 9493 included patients had an ICU-acquired infection. ICU-acquired pneumonia (47%) and ICU-acquired bloodstream infection (BSI) (37%) were the most frequently reported infections. Another recent multicentre study was conducted in 189 ICUs 4. Of the 3147 included patients, 12% had an ICU-acquired sepsis. ICU-acquired infections are frequently advocated as a significant contributor to mortality and morbidity 56. Identifying risk factor for healthcare-associated infections could be helpful for future studies aiming at preventing these infections.

Sedative and analgesic medications are routinely used in mechanically ventilated patients to reduce pain and anxiety and to allow patients to tolerate invasive procedures in the ICU 7. Mostly a combination of an opioid, to provide analgesia, and a hypnotic, such as benzodiazepines or propofol to provide anxiolysis, is used. A variety of opioids used by intravenous administration in adults are available for use in the ICU, including morphine, fentanyl, alfentanil, sufentanil and remifentanil 8. The use of fentanil, alfentanil and sufentanil, as well as morphine, is always accompanied by concerns regarding drug accumulation. In contrast, remifentanil is a short-acting opioid which is characterised by a rapid and uniform clearance and a highly predictable onset and offset of effect 9. Recently, negative effects of opioid withdrawal on the immune system were reported in opiate abusers 1011. In addition, animal studies suggested that morphine withdrawal induces immunosuppression resulting in an increased risk of infection 1213. We hypothesised that remifentanil discontinuation would be associated with a higher risk for subsequent ICU-acquired infection.

Materials and methods

Study design

This prospective observational cohort study was conducted in a 30-bed medical and surgical university ICU from December 2006 to December 2007. In accordance with the French law, approval by the local Institutional Review Board and informed consent was not required, given that this observational study did not modify current diagnostic or therapeutic strategies. All patients hospitalised in the ICU for more than 48 hours were eligible for this study.

Study population

The infection control policy included isolation techniques, routine screening of multidrug-resistant (MDR) bacteria, written antibiotic treatment protocol and continuous surveillance of nosocomial infections. Isolation techniques were performed in all patients with colonisation or infection related to MDR bacteria and in all immunosuppressed patients 14. These techniques included protective gowns and gloves usage associated with adequate hand hygiene using alcohol-based hand rub formulation before and after patient contacts. No selective digestive decontamination was performed.

Sedation protocol

Sedation was based on a written protocol including remifentanil with or without midazolam. Ramsay score was used to evaluate consciousness 15. The target Ramsay score was determined by the physicians. The bedside nurse adjusted sedative infusion to obtain target sedation level. Remifentanil was first used to obtain the sedation target and infusion of remifentanil could be increased every five minutes. If maximal dose of remifentanil was insufficient to obtain the prescribed Ramsay score, midazolam infusion was started and adjusted by the bed-side nurse. For example, in a patient weighing 60 kg, midazolam was started if remifentanil was insufficient to obtain the target Ramsay score at 58 mg/day. No daily interruption of sedation was performed. Sedation discontinuation was at the physician's discretion. However, in patients who received a combination of remifentanil and midazolam, midazolam was always discontinued before or at the same time as remifentanil. Acute withdrawal was treated by levomepronazin and lorazepam. Propofol infusion was used to treat acute withdrawal refractory to these medications.

Data collection

All data were prospectively collected. At ICU admission, the following data were collected: age; gender; simplified acute physiology score (SAPS) II 16; logistic organ dysfunction score 16; McCabe score; admission category; presence of comorbidities, including chronic obstructive pulmonary disease 17, chronic heart failure, immunosuppression 14 and diabetes mellitus; presence of infection; prior antibiotic treatment; and length of hospital stay before ICU admission. During ICU stay, the following data were collected: central venous and arterial catheter use; urinary tract catheter use; mechanical ventilation; duration of use of catheters and mechanical ventilation; reintubation; tracheostomy; fibreoptic bronchoscopy; digestive tract endoscopy; antimicrobial treatment; duration of antimicrobial treatment; remifentanil and midazolam use; duration and doses of remifentanil and midazolam used; discontinuation of remifentanil and midazolam; neuromuscular blocking agent use; and acute withdrawal. Information on length of ICU stay and ICU mortality was also collected.

Definitions

Sedation discontinuation was defined as an interruption of all sedatives for at least 24 hours, except those medications given to treat acute withdrawal. Acute withdrawal was defined by the presence of at least five of the following criteria 18 during the six hours following sedation discontinuation: fever (> 38°C), tachycardia (> 100 beats/minute), hypertension (mean arterial pressure > 100 mmHg), sweating, mydriasis, diarrhoea, nausea/vomiting and restlessness. Infection was considered as ICU-acquired if it was diagnosed more than 48 hours after ICU admission. ICU-acquired infections occurring less than five days after ICU admission were considered as early onset. Late-onset ICU-acquired infections were defined as those infections diagnosed five days or more after ICU admission.

Ventilator-associated pneumonia (VAP) was defined by the presence of new or progressive radiographic infiltrate associated with two of the following criteria: temperature above 38.5°C or below 36.5°C; leukocyte count greater than 10000 cells/μL or less than 1500 cells/μl; purulent tracheal aspirate. In addition, a positive tracheal aspirate (≥ 10⁶colony-forming units (cfu)/ml); or bronchoalveolar lavage (≥ 10⁴cfu/ml) was required 19.

BSI was defined as onset of infection associated with one or more positive blood culture result unrelated to an infection incubating at ICU admission. Coagulase-negative Staphylococcus BSI was defined as two or more positive blood cultures on separate occasions within a 48-hour period, or at least one blood culture positive with clinical sepsis, no other infectious process and antibiotic treatment given by the attending physician 20. Ventilator-associated tracheobronchitis was defined by all of the following criteria: fever (>38°C) with no other recognisable cause, purulent sputum production, positive (≥ 10⁶cfu/ml) endotracheal aspirate culture and no radiographic signs of new pneumonia 21. All Other ICU-acquired infections were defined according to modified Centers for Disease Control and Prevention criteria 22. Only infections confirmed by microbiological results were taken into account.

Incidence rate was defined as the number of ICU-acquired infections divided by the number of days at risk for these infections. Prior antibiotic treatment was defined as any antibiotic treatment during the four weeks preceding ICU-admission. MDR bacteria were defined as methicillin-resistant Staphylococcus aureus, ceftazidime or imipenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia and extending spectrum β-lactamase producing Gram-negative bacilli 19. During the study period, no vancomycin-resistant Enterococcus was isolated in the ICU.

Statistical methods

SPSS 11.5 software (SPSS, Chicago, IL, USA) was used for data analysis. Results are presented as number (percentage) for categorical variables, and mean ± standard deviation for quantitative variables. Distribution of quantitative variables was tested. All P values were two-tailed. The statistical significance was defined as P < 0.05.

Univariate analysis was used to determine factors associated with ICU-acquired infection. All the above cited variables were included in this analysis. Qualitative variables were compared using the Pearson chi-square test or the Fisher's exact test, as appropriate. Quantitative variables were compared using the Mann-Whitney U test or the Student's t-test, as appropriate. In patients with ICU-acquired infection, exposure to potential risk factors was taken into account until occurrence of the last ICU-acquired infection. For example, remifentanil discontinuation was considered a risk factor if it occurred before ICU-acquired infection. In patients without ICU-acquired infection, exposure to potential risk factors was taken into account until ICU discharge. Similarly, length of hospital stay was taken into account until ICU discharge in patients without ICU-acquired infection, and until the last ICU-acquired infection in patients with ICU-acquired infection. Patients with several ICU-acquired infections were considered at risk until the occurrence of the last infection.

Multivariate analysis was used to determine factors independently associated with ICU-acquired infection. All predictors showing a P < 0.1 association with ICU-acquired infection in univariate analysis were incorporated in the multivariate logistic regression analysis. Potential interactions were tested. Odds ratio (OR) and 95% confidence interval (CI) were calculated, as well as the Hosmer-Lemshow goodness-of-fit.

In the subgroup of patients who received remifentanil for at least 96 hours before discontinuation, incidence rate of ICU-acquired infection, duration of antimicrobial treatment and rate of patients with antimicrobial treatment discontinuation were compared between the two periods of 96 hours before and after remifentanil discontinuation. Further, incidence rate of ICU-acquired infection was compared between the 96 hours following remifentanil discontinuation and the whole ICU stay. Patients who died before remifentanil discontinuation were excluded from this analysis. For these comparisons, paired student's t test, and McNemar's test were used for quantitative and categorical variables, respectively. In this subgroup, characteristics of patients with or without ICU-acquired infection were compared at ICU admission.

Results

During the study period, 587 patients were hospitalised in the ICU for more than 48 hours, and were all included in the study. Patient characteristics at ICU admission, and during ICU stay are presented in Table 1 and Table 2, respectively.

Table 1

Characteristics of study patients at intensive care unit admission

Characteristic

ICU-acquired infection

n = 233

No ICU-acquired infection

n = 354

P value

Age

61 ± 14

57 ± 16

< 0.001

Male gender

161 (69)

244 (68)

> 0.999

SAPS II

54 ± 17

51 ± 20

< 0.001

LOD score

5.8 ± 3.6

4.6 ± 3.6

< 0.001

McCabe score

0.006

Nonfatal underlying disease

95 (40)

181 (51)

Ultimately fatal underlying disease

100 (42)

142 (40)

Rapidly fatal underlying disease

38 (16)

31 (8)

Glasgow coma score

11 ± 2

12 ± 2

0.651

Admission category

0.129

Medical

161 (69)

266 (75)

Surgical

72 (30)

88 (24)

Transfer from other wards

166 (71)

198 (55)

< 0.001*

Comorbidities

COPD

63 (27)

101 (28)

0.708

Chronic heart failure

55 (23)

72 (20)

0.358

Immunosuppression

60 (25)

68 (19)

0.066

Diabetes mellitus

34 (14)

78 (22)

0.025†

Infection

156 (66)

204 (57)

0.025‡

Prior antibiotic treatment

112 (48)

151 (42)

0.204

Length of prior hospital stay, days, median (interquartile range)

2 (0 to 6)

1 (0 to 3)

< 0.001

Data are presented as mean ± standard deviation or number (%), unless otherwise specified.

*Odds ratio = 1.95, 95% confidence interval = 1.37 to 2.77; †Odds ratio = 0.60, 95% confidence interval = 0.38 to 0.94; ‡Odds ratio = 1.49, 95% confidence interval = 1.05 to 2.10.

COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; LOD = logistic organ dysfunction; SAPS = simplified acute physiology score.

Table 2

Characteristics of study patients during intensive care unit stay

Characteristic

ICU-acquired infection

n = 233

No ICU-acquired infection

n = 354

P value

OR (95% CI)

Central venous catheter

224 (96)

246 (69)

< 0.001

10.9 (5.40 to 22.08)

Duration of central venous catheter use, days

25 ± 19

13 ± 9

< 0.001

Arterial catheter

218 (93)

218 (61)

< 0.001

9.06 (5.15 to 15.9)

Duration of arterial catheter use, days

25 ± 19

12 ± 7

< 0.001

Urinary catheter

223 (95)

281 (79)

< 0.001

5.79 (2.92 to 11.47)

Duration of urinary catheter use, days

25 ± 19

13 ± 9

< 0.001

Mechanical ventilation

225 (96)

244 (68)

< 0.001

12.6 (6.04 to 26.5)

Duration of mechanical ventilation, days

24 ± 18

11 ± 7

< 0.001

Reintubation

33 (14)

18 (5)

< 0.001

3.08 (1.69 to 5.61)

Tracheostomy

55 (23)

24 (6)

< 0.001

4.24 (2.54 to 7.09)

Fibreoptic bronchoscopy

140 (60)

93 (26)

< 0.001

4.22 (2.96 to 6.01)

Digestive tract endoscopy

52 (22)

32 (9)

< 0.001

2.89 (1.79 to 4.65)

Antimicrobial treatment

211 (90)

286 (80)

0.001

2.28 (1.36 to 3.80)

Duration of antimicrobial treatment, days

19 ± 16

11 ± 6

< 0.001

Remifentanil use

203 (87)

191 (53)

< 0.001

5.77 (3.73 to 8.93)

Duration of remifentanil use, days

12 ± 11

7 ± 4

< 0.001

Dose of remifentanil, mg/kg/day

0.73 ± 0.25

0.61 ± 0.21

0.083

Remifentanil discontinuation

153 (65)

133 (37)

< 0.001

3.17 (2.24 to 4.49)

Midazolam use

136 (58)

106 (29)

< 0.001

3.28 (2.32 to 4.63)

Duration of midazolam use, days

9 ± 7

5 ± 4

< 0.001

Dose of midazolam, mg/kg/days

1.76 ± 0.91

1.36 ± 0.70

0.183

Midazolam discontinuation

86 (36)

73 (20)

< 0.001

2.25 (1.55 to 3.26)

Ramsay score

3.6 ± 1

2.7 ± 1

0.043

Neuromuscular blocking agent use

36 (15)

25 (7)

0.001

2.40 (1.40 to 4.12)

Acute withdrawal

48 (20)

32 (9)

< 0.001

2.61 (1.61 to 4.23)

Length of stay before ICU-acquired infection, days

24 ± 19

11 ± 8

< 0.001

Data are presented as mean ± SD or number (%).

In patients with ICU-acquired infection, exposure to potential risk factors was taken into account until occurrence of the last ICU-acquired infection. In patients without ICU-acquired infection, exposure to potential risk factors was taken into account until ICU-discharge.

ICU, intensive care unit; OR = odds ratio; SD = standard deviation.

In 233 (39%) patients, 477 microbiologically confirmed ICU-acquired infections were diagnosed. Incidence rate of ICU-acquired infection was 38 per1000 ICU days. VAP was the most frequently diagnosed ICU-acquired infection (17 per 1000 mechanical ventilation days), followed by ICU-acquired BSI (9 per 1000 ICU days), ICU-acquired urinary tract infection (8 per 1000 urinary catheter days), ventilator-associated tracheobronchitis (8 per 1000 mechanical ventilation days), catheter-related infection (2 per 1000 catheter days) and other infections (1 per 1000 ICU days). Of 233 patients with ICU-acquired infection, 198 (84%) had at least one episode of VAP or ICU-acquired BSI. P. aeruginosa was the most frequently isolated bacteria (30%), followed by Enterobacter species (13%) and S. aureus (10%). Twenty-eight (5%) ICU-acquired infections were polymicrobial and 151 (33%) ICU-acquired infections were related to MDR bacteria. Sixty-eight (14%) ICU-acquired infections were early onset, and mean time from ICU admission to first ICU-acquired infection was 11 ± 8 days.

Among the 394 patients who received sedation during the ICU stay, 90 patients died before remifentanil discontinuation. Remifentanil was discontinued in 304 patients, including 286 patients in which remifentanil was discontinued before ICU-acquired infection and 18 patients in which remifentanil was discontinued after ICU-acquired infection. No significant difference was found in the reintubation rate between patients with remifentanil discontinuation and patients without remifentanil discontinuation (29 of 304 (9%) vs 22 of 283 (7%), P = 0.242). Mean time from remifentanil discontinuation to subsequent ICU-acquired infection was 4 ± 3 days.

Risk factors for ICU-acquired infection

Several factors were significantly associated with ICU-acquired infection by univariate analysis at ICU-admission and during ICU stay (Tables 1 and 2).

Multivariate analysis identified remifentanil discontinuation, SAPS II at ICU admission, mechanical ventilation, tracheostomy, central venous catheter and length of hospital stay as independent risk factors for ICU-acquired infection (Table 3).

Table 3

Risk factors for ICU-acquired infection by multivariate analysis

95% CI

Remifentanil discontinuation

2.53

1.28 to 4.99

0.007

SAPS II at ICU admission

1.01*

1 to 1.03

0.011

Mechanical ventilation

4.49

1.52 to 13.2

0.006

Tracheostomy

2.25

1.13 to 4.48

0.021

Central venous catheter

2.9

1.08 to 7.74

0.033

Length of hospital stay

1.05*

1.03 to 1.08

< 0.001

*Per point of SAPS II, and per day; respectively.

Lemeshow goodness-of-fit test, P = 0.86.

CI = confidence interval; ICU = intensive care unit; OR = odds ratio; SAPS = simplified acute physiology score.

Outcomes

Duration of mechanical ventilation (33 ± 23 vs 11 ± 7 days, P < 0.001), length of ICU stay (38 ± 30 vs 14 ± 9 days, P < 0.001) and ICU mortality (108 of 233 (46%) vs 90 of 354 (25%), P < 0.001, OR = 2.53, 95% CI = 1.78 to 3.60) were significantly higher in patients with ICU-acquired infection compared with patients without ICU-acquired infection, respectively.

Incidence rate of ICU-acquired infection before and after remifentanil discontinuation

Characteristics of the subgroup of patients who received remifentanil for at least 96 hours before discontinuation (n = 266) are presented in Table 4. In this subgroup, incidence rate of ICU-acquired infection was significantly higher during the 96 hours following remifentanil discontinuation compared with the 96 hours preceding remifentanil discontinuation (94 ± 192 vs 29 ± 103 per 1000 ICU days, P < 0.001) and compared with the whole ICU stay (94 ± 192 vs 40 ± 46 per 1000 ICU days, P < 0.001). In these patients, the highest rate of ICU-acquired infection was observed on day four after remifentanil discontinuation (Figure 1). Duration of antimicrobial treatment (3 ± 2 vs 2 ± 1 days, P = 0.182) and antimicrobial discontinuation rate (51 of 266 (19%) vs 69 of 266 (25%), P = 0.121) were similar during the two periods of 96 hours before and after remifentanil discontinuation, respectively.

Figure 1

Distribution of ICU-acquired infections according to remifentanil discontinuation in patients who received remifentanil for 96 hours of more before discontinuation

Distribution of ICU-acquired infections according to remifentanil discontinuation in patients who received remifentanil for 96 hours of more before discontinuation. Mean (standard deviation) length of intensive care unit (ICU) stay was 29 ± 28 days, including 17 ± 7 days before the first ICU-acquired infection.

Table 4

Characteristics at ICU admission of patients who received remifentanil for 96 hours or more before discontinuation

Characteristic

ICU-acquired infection

n = 153

No ICU-acquired infection

n = 113

P value

Age

61 ± 14

53 ± 16

< 0.001

Male gender

100 (65)

78 (69)

0.620

SAPS II

51 ± 16

47 ± 19

0.035

LOD score

5.5 ± 3.4

5.2 ± 3.3

0.435

McCabe score

0.028

Nonfatal underlying disease

67 (43)

67 (59)

Ultimately fatal underlying disease

69 (45)

40 (35)

Rapidly fatal underlying disease

17 (11)

6 (5)

Glasgow coma score

10 ± 2

11 ± 2

0.651

Admission category

> 0.999

Medical

110 (71)

82 (72)

Surgical

43 (28)

31 (27)

Transfer from other wards

107 (69)

63 (55)

< 0.024*

Comorbidities

COPD

42 (27)

38 (33)

0.342

Chronic heart failure

37 (24)

20 (17)

0.262

Immunosuppression

34 (22)

20 (17)

0.452

Diabetes mellitus

24 (15)

30 (26)

0.043†

Infection

103 (67)

73 (64)

0.740

Prior antibiotic treatment

76 (49)

51 (45)

0.543

Length of prior hospital stay, days (interquartile range)

1 (0 to 2)

1 (0 to 5)

0.737

Data are presented as mean ± standard deviation or number (%), unless otherwise specified.

* Odds ratio = 1.84, 95% confidence interval = 1.11 to 3.06; † Odds ratio = 0.51, 95% confidence interval = 0.28 to 0.94.

COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; LOD = logistic organ dysfunction; SAPS = simplified acute physiology score.

Discussion

Multivariate analysis identified remifentanil discontinuation, SAPS II at ICU admission, use of mechanical ventilation, tracheostomy, central venous catheter and length of hospital stay as independent risk factors for ICU-acquired infection. All these factors, except remifentanil discontinuation, were identified by previous studies as important risk factors for health care-associated infections 223242526. To our knowledge, our study is the first clinical study to evaluate the impact of opioid discontinuation on ICU-acquired infection 27.

Several potential explanations could be provided for the association between remifentanil discontinuation and ICU-acquired infection. First, higher rates of reintubation could be observed after discontinuation of sedation. Reintubation is a well-known risk factor for aspiration and VAP 28. However, no significant difference was found in reintubation rate between patients with remifentanil discontinuation compared with patients without remifentanil discontinuation. In addition, reintubation was not independently associated with ICU-acquired infection. Second, antibiotic discontinuation may have influenced our results. Several studies demonstrated that systemic antibiotic treatment was associated with reduced rates of early-onset ICU-acquired infections 2930. On the other hand, other studies demonstrated that antibiotic treatment was a risk factor for subsequent infections related to MDR bacteria 3132. However, in the subgroup of patients sedated for at least 96 hours before discontinuation, duration of antimicrobial treatment and rate of patients with antimicrobial treatment discontinuation were similar during the two periods of 96 hours preceding and following remifentanil discontinuation. Third, the higher rate of ICU-acquired infection after remifentanil discontinuation could be related to immunosuppressive effects observed after opioid withdrawal.

Previous animal studies found morphine withdrawal to be associated with higher rates of infection. In mice exposed to morphine for 96 hours, the effect of morphine withdrawal on spontaneous sepsis and on oral infection with Salmonella enterica was recently examined 13. Withdrawal significantly increased the Salmonella burden in various tissues of infected mice compared with animals who had placebo withdrawn and decreased the mean survival time. Elevated levels of proinflammatory cytokines were observed in the spleens of mice who had morphine withdrawn, compared with mice who had placebo withdrawn. The same authors 12 demonstrated a correlation between the suppression of IL-12 production and an increased susceptibility to Salmonella infection in mice undergoing withdrawal from morphine. Further, in another animal study, morphine withdrawal sensitised the animals to lipopolysaccharide lethality via increased production of TNF-α and nitric oxide 33.

In rats, immunomodulatory effects of morphine withdrawal were investigated alone and in the presence of the α-2-adrenergic agonist, clonidine 34. Weight change was observed with peak decreases in weight occurring 24 hours after withdrawal. Rats withdrawn from morphine also exhibited a time-dependent suppression of immune status with significantly altered proliferation of T-cells stimulated by concanavalin A, altered proliferation of splenic T-cells stimulated by toxic shock syndrome toxin-1, altered production of the interferon-γ by concanavalin A-stimulated splenocytes and significantly altered natural-killer cell activity. These immunomodulatory effects were most evident 12 hours following morphine withdrawal. In addition, clonidine prevented withdrawal-induced immunosuppression. Other recent animal studies 3510 confirmed these results and suggested that abrupt cessation of morphine administration resulted in an activation of stress-related pathways that may contribute to an increased susceptibility of infection during the initial withdrawal phase. These suppressive effects on the immune system were significant for up to 72 hours after withdrawal from chronic morphine. Our results are consistent with these findings because a peak of ICU-acquired infection was observed at day four after remifentanil discontinuation. Disturbances of the stress axis were reported to have a major impact on infections, including higher rates of postoperative pneumonia in long-term alcoholics 36. A recent randomised controlled study, performed in long-term alcoholics, suggested that intervention at the level of the hypothalamus-pituitary-adrenal axis altered the immune response to surgical stress 37. This resulted in decreased post-operative pneumonia rates and shortened ICU stay in these patients.

There are biological, as well as pathological, interactions between neuropeptide substance P, which is a modulator of neuroimmunoregulation, and opiates 38. In an in vitro model, Wang and colleagues 39 investigated the relationship between morphine withdrawal and HIV infection of human T lymphocytes. They concluded that the interaction of opiates and neuropeptide substance P in human T lymphocytes was likely to a have a role in the immunopathogenesis of HIV disease among opiate abusers.

Prevalence of ICU-acquired infection and duration of sedation were high in our study. This could be explained by the high severity of our patients at ICU admission, the large proportion of patients with comorbidities and the high proportion of patients requiring mechanical ventilation. These factors are well known to be associated with prolonged ICU stay and higher risk for ICU-acquired infection 19. A recent study was performed in 151 ICUs in France, including 30% of university ICUs 40. During a six-month period, 20,632 patients were included in the study. Incidence rates of ICU-acquired infection were consistent with our findings, including 17.5 VAP cases per 1000 mechanical ventilation days, 2.2 catheter-related infections per 1000 catheter days, 3.3 BSI per 1000 ICU days and 7.8 urinary tract infections per 1000 urinary catheter days. Some of the ICU-acquired infections evaluated by our study could be difficult to differentiate from colonisation such as ventilator-associated tracheobronchitis and urinary tract infection. To adjust for this potential confounder, we have repeated all analyses taking into account only ICU-acquired BSI and VAP. Similar results were found (data not shown), and remifentanil discontinuation was still independently associated with ICU-acquired BSI and VAP.

It could be argued that the higher incidence rate of ICU-acquired infection during the 96 hours following sedation discontinuation, found by our study, could simply reflect the fact that the cumulative risk of ICU-acquired infection was higher during this period compared with the 96 hours preceding sedation discontinuation. However, although the cumulative risk for ICU-acquired infection was higher during the whole ICU stay compared with the 96 hours following sedation discontinuation, incidence rate of ICU-acquired infection was higher during the 96 hours following sedation discontinuation compared with the whole ICU stay. Additionally, remifentanil discontinuation was independently associated with ICU-acquired infection.

Daily sedation interruption was not performed in this study. However, a nurse-adjusted sedation protocol was used. A recent randomised controlled study compared nursing-implemented sedation algorithm with daily interruption of sedation 41. The authors found the sedation algorithm to be associated with reduced duration of mechanical ventilation and lengths of stay compared with daily interruption of sedation. In addition, a recent web-based survey was performed on members of the Society of Critical Care Medicine 42. Daily interruption of sedation was only performed by 40% of the 904 responders. Another recent survey demonstrated that none of the 44 participating ICUs were conducting daily interruption of sedation 43.

Our study has some limitations. First, this was a single centre study and the results may not be generalisable to other ICUs. Second, our study was observational, and further randomised studies are needed to confirm these results. Third, remifentanil was used for sedation. Whether our results are applicable to patients sedated with other opioids is unknown. A recent in vitro study found remifentanil, but not sufentanil or alfentanil, to attenuate lipopolysaccharide-induced neutrophil responses and neutrophil-mediated inflammatory responses 44. Fourth, midazolam was used in a large proportion of patients sedated with remifentanil. Therefore, midazolam discontinuation may have influenced the subsequent ICU-acquired infection. However, midazolam use and discontinuation were not independently associated with ICU-acquired infection. Fifth, our risk analysis did not account for the patient's condition on the day of remifentanil discontinuation. However, a different study design, such as a matched-controlled study, would be more appropriate to adjust for this potential confounder. Finally, although remifentanil discontinuation was an independent risk factor for ICU-acquired infection, acute withdrawal was not independently associated with ICU-acquired infection. One potential explanation is the fact that our definition of acute withdrawal was stringent resulting in possible underestimation of acute withdrawal frequency. However, no relationship between infection and clinical signs of abstinence has been reported by animal studies 1213.

Conclusions

We conclude that remifentanil discontinuation is associated with a higher risk of ICU-acquired infections. Further randomised studies are needed to confirm these results.

Key messages

• Remifentanil discontinuation is independently associated with a higher risk for ICU-acquired infections.

• Further randomised studies are needed to confirm these results.

Abbreviations

BSI: bloodstream infection; cfu: colony forming units; CI: confidence interval; ICU: intensive care unit; IL: interleukin; MDR: multidrug-resistant; OR: odds ratio; SAPS: simplified acute physiology score; TNF: tumour necrosis factor; VAP: ventilator-associated pneumonia.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SN, DM and AD designed the study. SN, JH, GG and ASL collected the data. CDP performed statistical analyses. SN wrote the manuscript, and all authors participated in its critical revision. SN had full access to all data in the study and had final responsibility for the decision to submit for publication. All authors read and approved the final manuscript.

Acknowledgements

This study was presented in part at the 21^stCongress of the European Society of Intensive Care Medicine, Lisbon, Portugal (21 to 24 September 2008).

Infection control – a problem for patient safety Burke JP N Engl J Med 2003 348 651 656 10.1056/NEJMhpr020557 12584377 The effect of workload on infection risk in critically ill patients Hugonnet S Chevrolet JC Pittet D Crit Care Med 2007 35 76 81 10.1097/01.CCM.0000251125.08629.3F 17095946 Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9,493 patients from 71 Italian intensive care units Malacarne P Langer M Nascimben E Moro ML Giudici D Lampati L Bertolini G Crit Care Med 2008 36 1105 1113 10.1097/CCM.0b013e318169ed30 18379234 Sepsis in European intensive care units: results of the SOAP study Vincent JL Sakr Y Sprung CL Ranieri VM Reinhart K Gerlach H Moreno R Carlet J Le Gall JR Payen D Crit Care Med 2006 34 344 353 10.1097/01.CCM.0000194725.48928.3A 16424713 Educational interventions for prevention of healthcare-associated infection: a systematic review Safdar N Abad C Crit Care Med 2008 36 933 940 10.1097/CCM.0B013E318165FAF3 18431283 Impact of ventilator-associated pneumonia on outcome in patients with COPD Nseir S Di Pompeo C Soubrier S Cavestri B Jozefowicz E Saulnier F Durocher A Chest 2005 128 1650 1656 10.1378/chest.128.3.1650 16162771 Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult Jacobi J Fraser GL Coursin DB Riker RR Fontaine D Wittbrodt ET Chalfin DB Masica MF Bjerke HS Coplin WM Crippen DW Fuchs BD Kelleher RM Marik PE Nasraway SA Jr Murray MJ Peruzzi WT Lumb PD Crit Care Med 2002 30 119 141 10.1097/00003246-200201000-00020 11902253 Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial Muellejans B Matthey T Scholpp J Schill M Crit Care 2006 10 R91 1550941 16780597 10.1186/cc4939 The place for short-acting opioids: special emphasis on remifentanil Wilhelm W Kreuer S Crit Care 2008 12 Suppl 3 S5 2391266 18495056 Abrupt or precipitated withdrawal from morphine induces immunosuppression Rahim RT Adler MW Meissler JJ Jr Cowan A Rogers TJ Geller EB Eisenstein TK J Neuroimmunol 2002 127 88 95 10.1016/S0165-5728(02)00103-0 12044979 Alterations of immune functions in heroin addicts and heroin withdrawal subjects Govitrapong P Suttitum T Kotchabhakdi N Uneklabh T J Pharmacol Exp Ther 1998 286 883 889 9694946 Increased sensitivity to Salmonella enterica serovar Typhimurium infection in mice undergoing withdrawal from morphine is associated with suppression of interleukin-12 Feng P Wilson QM Meissler JJ Jr Adler MW Eisenstein TK Infect Immun 2005 73 7953 7959 1307081 16299287 10.1128/IAI.73.12.7953-7959.2005 Morphine withdrawal lowers host defense to enteric bacteria: spontaneous sepsis and increased sensitivity to oral Salmonella enterica serovar Typhimurium infection Feng P Truant AL Meissler JJ Jr Gaughan JP Adler MW Eisenstein TK Infect Immun 2006 74 5221 5226 1594820 16926415 10.1128/IAI.00208-06 Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study Nseir S Di Pompeo C Diarra M Brisson H Tissier S Boulo M Durocher A Crit Care Med 2007 35 1318 1323 10.1097/01.CCM.0000261885.50604.20 17414081 Controlled sedation with alphaxalone-alphadolone Ramsay MA Savege TM Simpson BR Goodwin R BMJ 1974 2 656 659 1613102 4835444 10.1136/bmj.2.5920.656 A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study Le Gall JR Lemeshow S Saulnier F JAMA 1993 270 2957 2963 8254858 10.1001/jama.270.24.2957 Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Celli BR MacNee W Eur Respir J 2004 23 932 946 10.1183/09031936.04.00014304 15219010 Withdrawal following sufentanil/propofol and sufentanil/midazolam. Sedation in surgical ICU patients: correlation with central nervous parameters and endogenous opioids Korak-Leiter M Likar R Oher M Trampitsch E Ziervogel G Levy JV Freye EC Intensive Care Med 2005 31 380 387 10.1007/s00134-005-2579-3 15714323 Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Niederman MS Craven D Am J Respir Crit Care Med 2005 171 388 416 10.1164/rccm.200405-644ST 15699079 Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay Martin MA Pfaller MA Wenzel RP Ann Intern Med 1989 110 9 16 2908834 Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study Nseir S Favory R Jozefowicz E Decamps F Dewavrin F Brunin G Di Pompeo C Mathieu D Durocher A Crit Care 2008 12 R62 2481443 18454864 10.1186/cc6890 CDC definitions for nosocomial infections, 1988 Garner JS Jarvis WR Emori TG Horan TC Hughes JM Am J Infect Control 1988 16 128 140 10.1016/0196-6553(88)90053-3 2841893 Incidence and risk factors of device-associated infections and associated mortality at the intensive care in the Dutch surveillance system Kooi van der TI de Boer AS Mannien J Wille JC Beaumont MT Mooi BW van den HS Intensive Care Med 2007 33 271 278 10.1007/s00134-006-0464-3 17146632 Prospective study of peripheral arterial catheter infection and comparison with concurrently sited central venous catheters Koh DB Gowardman JR Rickard CM Robertson IK Brown A Crit Care Med 2008 36 397 402 10.1097/CCM.0b013e318161f74b 18216598 Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study Alp E Guven M Yildiz O Aygen B Voss A Doganay M Ann Clin Microbiol Antimicrob 2004 3 17 521500 15369593 10.1186/1476-0711-3-17 Incidence and risk factors for ventilator-associated pneumonia in 4 multidisciplinary intensive care units in Athens, Greece Apostolopoulou E Bakakos P Katostaras T Gregorakos L Respir Care 2003 48 681 688 12841859 Opioids and Infections in the Intensive Care Unit Should Clinicians and Patients be Concerned? Weinert CR Kethireddy S Roy S J Neuroimmune Pharmacol 2008 3 218 229 10.1007/s11481-008-9124-4 18773298 Preventing ventilator-associated pneumonia in adults: sowing seeds of change Craven DE Chest 2006 130 251 260 10.1378/chest.130.1.251 16840410 Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study Acquarolo A Urli T Perone G Giannotti C Candiani A Latronico N Intensive Care Med 2005 31 510 516 10.1007/s00134-005-2585-5 15754197 Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma Sirvent JM Torres A El Ebiary M Castro P de Batlle J Bonet A Am J Respir Crit Care Med 1997 155 1729 1734 9154884 Relationship between tracheotomy and ventilator-associated pneumonia: a case control study Nseir S Di Pompeo C Jozefowicz E Cavestri B Brisson H Nyunga M Soubrier S Durocher A Eur Respir J 2007 30 314 320 10.1183/09031936.06.00024906 16870667 Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome Nseir S Di Pompeo C Brisson H Dewavrin F Tissier S Diarra M Boulo M Durocher A Crit Care 2006 10 R143 1751051 17026755 10.1186/cc5063 Morphine withdrawal sensitizes mice to lipopolysaccharide: elevated TNF-alpha and nitric oxide with decreased IL-12 Feng P Meissler JJ Jr Adler MW Eisenstein TK J Neuroimmunol 2005 164 57 65 10.1016/j.jneuroim.2005.03.017 15913793 Immunomodulatory effects of morphine withdrawal in the rat are time dependent and reversible by clonidine West JP Dykstra LA Lysle DT Psychopharmacology (Berl) 1999 146 320 327 10.1007/s002130051123 10541733 Immune cell activity during the initial stages of withdrawal from chronic exposure to cocaine or morphine Avila AH Alonzo NC Bayer BM J Neuroimmunol 2004 147 109 113 10.1016/j.jneuroim.2003.10.023 14741439 Altered cell-mediated immunity and increased postoperative infection rate in long-term alcoholic patients Spies CD von DV Eggers V Jetschmann G El Hilali R Egert J Fischer M Schroder T Hoflich C Sinha P Paschen C Mirsalim P Brunsch R Hopf J Marks C Wernecke KD Pragst F Ehrenreich H Muller C Tonnesen H Oelkers W Rohde W Stein C Kox WJ Anesthesiology 2004 100 1088 1100 10.1097/00000542-200405000-00010 15114205 Intervention at the level of the neuroendocrine-immune axis and postoperative pneumonia rate in long-term alcoholics Spies C Eggers V Szabo G Lau A von DV Schoenfeld H Althoff H Hegenscheid K Bohm B Schroeder T Pfeiffer S Ziemer S Paschen C Klein M Marks C Miller P Sander M Wernecke KD Achterberg E Kaisers U Volk HD Am J Respir Crit Care Med 2006 174 408 414 10.1164/rccm.200506-907OC 16728716 Sub-chronic exposure to opiates in the rat: effects on brain levels of substance P and calcitonin gene-related peptide during dependence and withdrawal Tiong GK Pierce TL Olley JE J Neurosci Res 1992 32 569 575 10.1002/jnr.490320412 1382137 An in vitro model of morphine withdrawal manifests the enhancing effect on human immunodeficiency virus infection of human T lymphocytes through the induction of substance P Wang X Douglas SD Peng JS Zhou DJ Wan Q Ho WZ Am J Pathol 2006 169 1663 1670 1780221 17071590 10.2353/ajpath.2006.060358 REA-RAISIN 2005: Surveillance of ICU-aquired infections in adult critically ill patients in France http://www.invs.sante.fr Randomized trial comparing daily interruption of sedation and nursing-implemented sedation algorithm in medical intensive care unit patients de Wit M Gennings C Jenvey WI Epstein SK Crit Care 2008 12 R70 2481461 18492267 10.1186/cc6908 Perceived barriers to the use of sedation protocols and daily sedation interruption: A multidisciplinary survey Tanios MA de Wit M Epstein SK Devlin JW J Crit Care 2009 24 66 73 10.1016/j.jcrc.2008.03.037 19272541 Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study Payen JF Chanques G Mantz J Hercule C Auriant I Leguillou JL Binhas M Genty C Rolland C Bosson JL Anesthesiology 2007 106 687 695 10.1097/01.anes.0000264747.09017.da 17413906 Remifentanil attenuates LPS-induced neutrophil activation Kwak S Chung S Li M Bae H Crit Care Med 2008 35 A60 (abstract)